New heart-failure therapy takes race into account.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Subject Terms:
      NITROMED Inc. 825941636 ; UNITED States. Food & Drug Administration
    • Abstract:
      Reports that the United States Food and Drug Administration has approved the marketing of NitroMed Inc.'s heart-failure combination drug BiDil which is expressly for use in patients who identify themselves as black and need additional therapy. Combination of isosorbide dinitrate and hydralazine hydrochloride; NitroMed's use of a Veterans Administration Cooperative Study of men with heart failure; Results of the privately funded African-American Heart Failure Trial.